lan Molson - Alphatec Holdings Independent Director
ATEC Stock | USD 13.79 0.01 0.07% |
Director
Mr. R. lan Molson was Independent Director of Alphatec Holdings, Inc. Mr. Molson has served as a director of Cayzer Continuation PCC, an investment company, since September 2004. Mr. Molson has served as a director of HealthpointCapital, LLC since 2004. Mr. Molson has served as a director since December 2009 and Deputy Chairman since December 2010 of Central European Petroleum Ltd. Since October 2013, Mr. Molson has also served as Chairman of RM2. Since December 2010, Mr. Molson has also served as Chairman of the Royal Marsden NHS Foundation Trust and the Royal Marsden Hospital Charity. From 1996 until 2004, Mr. Molson served as a director of Molson, Inc., a leader in the brewing industry, and from 1999 until 2004, he also served as Deputy Chairman and Chairman of the Executive Committee at Molson, Inc. Between 1977 and 1997, he was employed by Credit Suisse First Boston in various capacities, including Managing Director. From 1993 to 1997, Mr. Molson served as CoHead of the Investment Banking Department in Europe, a position which encompassed corporate finance, corporate advisory, mergers and acquisitions businesses in Europe, Russia, Africa and the Middle East since 2005.
Age | 61 |
Tenure | 19 years |
Address | 1950 Camino Vida Roble, Carlsbad, CA, United States, 92008 |
Phone | 760 431 9286 |
Web | https://www.atecspine.com |
Alphatec Holdings Management Efficiency
The company has return on total asset (ROA) of (0.1398) % which means that it has lost $0.1398 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.1175) %, meaning that it created substantial loss on money invested by shareholders. Alphatec Holdings' management efficiency ratios could be used to measure how well Alphatec Holdings manages its routine affairs as well as how well it operates its assets and liabilities. As of March 28, 2024, Return On Capital Employed is expected to decline to -0.24. In addition to that, Return On Assets is expected to decline to -0.24. At present, Alphatec Holdings' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 371.8 M, whereas Other Assets are forecasted to decline to 0.95.Similar Executives
Showing other executives | DIRECTOR Age | ||
Peter Neupert | Laboratory | 65 | |
JeanLuc Belingard | Laboratory | 72 | |
Roman Martinez | Cigna Corp | 71 | |
Pascal Goldschmidt | Mednax Inc | 65 | |
Donna Zarcone | Cigna Corp | 63 | |
Waldemar Carlo | Mednax Inc | 67 | |
Jane Henney | Cigna Corp | 69 | |
Dipchand Nishar | Guardant Health | N/A | |
Karey Barker | Mednax Inc | 52 | |
Donna Shalala | Mednax Inc | 75 | |
James Rogers | Cigna Corp | 69 | |
Samir Kaul | Guardant Health | 44 | |
Eric Foss | Cigna Corp | 62 | |
Gary Gilliland | Laboratory | 63 | |
Sanders Williams | Laboratory | 69 | |
Manuel Kadre | Mednax Inc | 54 | |
Richelle Parham | Laboratory | 53 | |
Enrique Sosa | Mednax Inc | 79 | |
Kerrii Anderson | Laboratory | 63 | |
Mary Hoeltzel | Cigna Corp | N/A | |
Michelle Gass | Cigna Corp | 47 |
Management Performance
Return On Equity | -4.12 | ||||
Return On Asset | -0.14 |
Alphatec Holdings Leadership Team
Elected by the shareholders, the Alphatec Holdings' board of directors comprises two types of representatives: Alphatec Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alphatec. The board's role is to monitor Alphatec Holdings' management team and ensure that shareholders' interests are well served. Alphatec Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alphatec Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
Jeffrey Black, CFO, Executive Vice President | ||
John Foster, Director | ||
David Mowry, Independent Director | ||
Karen McGinnis, Independent Director | ||
Ali Shorooghi, Senior Marketing | ||
Jon Allen, Executive Vice President - Commercial Operations | ||
Leslie Cross, Chairman of the Board | ||
Rohit Desai, Independent Director | ||
Stephen ONeil, Independent Director | ||
Michael ONeill, CFO, Vice President Treasurer | ||
Stephen Lubischer, VP of Sales | ||
Michael Plunkett, COO | ||
Tom Davis, Independent Director | ||
Donald Williams, Independent Director | ||
Mortimer Berkowitz, Director | ||
Kristin Leary, Sr. VP of Global HR | ||
Jeffrey Rydin, Director | ||
Terry Rich, CEO, Director | ||
Jonathan Allen, Executive Vice President - Commercial Operations | ||
Quentin Blackford, Director | ||
Siri Marshall, Independent Director | ||
Christine Zedelmayer, IR Contact Officer | ||
James Corbett, CEO and President Director and Member of Executive Committee | ||
Dennis Nelson, Interim Principal Financial and Accounting Officer | ||
Patrick Miles, Chairman of the Board | ||
Lance Denardin, Vice President - West | ||
Scott Lish, Vice President - Development | ||
Brian Snider, Executive Vice President - Strategic Marketing and Product Development | ||
Ebun Garner, Senior Vice President General Counsel, Secretary | ||
James Tullis, Director | ||
Amy Ables, Vice President - Corporate Education & Performance | ||
lan Molson, Independent Director | ||
Michael Dendinger, Vice President - Operations | ||
Eric Dasso, Executive Technologies | ||
Evan Bakst, Director | ||
R Molson, Independent Director | ||
Tyson Marshall, General Secretary | ||
David Sponsel, Executive Vice President - Sales | ||
Mitsuo Asai, President of Alphatec Pacific Inc | ||
Kelli Howell, Executive Vice President - Clinical Strategies | ||
Ward Woods, Independent Director | ||
Luiz Pimenta, Chief Medical Officer | ||
Craig Hunsaker, Executive Vice President - People and Culture | ||
Todd Koning, Executive CFO | ||
Jason Hochberg, Director | ||
Mark Ojeda, Executive Vice President Cervical and Biologics |
Alphatec Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alphatec Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -4.12 | ||||
Return On Asset | -0.14 | ||||
Profit Margin | (0.39) % | ||||
Operating Margin | (0.25) % | ||||
Current Valuation | 2.17 B | ||||
Shares Outstanding | 137.98 M | ||||
Shares Owned By Insiders | 34.75 % | ||||
Shares Owned By Institutions | 67.10 % | ||||
Number Of Shares Shorted | 11.02 M | ||||
Price To Earning | (2.14) X |
Pair Trading with Alphatec Holdings
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alphatec Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alphatec Holdings will appreciate offsetting losses from the drop in the long position's value.Moving together with Alphatec Stock
0.79 | MMSI | Merit Medical Systems Financial Report 24th of April 2024 | PairCorr |
Moving against Alphatec Stock
0.81 | FEMY | Femasys Report 4th of April 2024 | PairCorr |
0.73 | NVNO | EnVVeno Medical Corp Financial Report 6th of May 2024 | PairCorr |
0.73 | CAH | Cardinal Health Sell-off Trend | PairCorr |
0.41 | XTNT | Xtant Medical Holdings | PairCorr |
The ability to find closely correlated positions to Alphatec Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alphatec Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alphatec Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alphatec Holdings to buy it.
The correlation of Alphatec Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alphatec Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alphatec Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alphatec Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alphatec Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. For information on how to trade Alphatec Stock refer to our How to Trade Alphatec Stock guide.Note that the Alphatec Holdings information on this page should be used as a complementary analysis to other Alphatec Holdings' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Alphatec Stock analysis
When running Alphatec Holdings' price analysis, check to measure Alphatec Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alphatec Holdings is operating at the current time. Most of Alphatec Holdings' value examination focuses on studying past and present price action to predict the probability of Alphatec Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alphatec Holdings' price. Additionally, you may evaluate how the addition of Alphatec Holdings to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Alphatec Holdings' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alphatec Holdings. If investors know Alphatec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alphatec Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.54) | Revenue Per Share 3.978 | Quarterly Revenue Growth 0.302 | Return On Assets (0.14) | Return On Equity (4.12) |
The market value of Alphatec Holdings is measured differently than its book value, which is the value of Alphatec that is recorded on the company's balance sheet. Investors also form their own opinion of Alphatec Holdings' value that differs from its market value or its book value, called intrinsic value, which is Alphatec Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alphatec Holdings' market value can be influenced by many factors that don't directly affect Alphatec Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alphatec Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alphatec Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alphatec Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.